Development and applications of mRNA treatment based on lipid nanoparticles

Wang, Zhe; Ma, Wanting; Fu, Xingxing; Zhao, Yinan; Zhang, Shubiao

doi:10.1016/j.biotechadv.2023.108130

Cited by 22 publications

(6 citation statements)

References 204 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 72 – 75 LNPs may be designed for stimuli-triggered release, but accuracy in physiological conditions remains a challenge. 76 – 79 Research and optimization are ongoing to address these limitations and enhance lipid NP performance.…”

Section: Advanced Nanotechnologiesmentioning

confidence: 99%

“…Existing studies prove that the successful delivery of drug-carrying NPs to target organs and tissues is related to the surface conditions of the target organ and the route of drug delivery. 76 , 628 – 631 However, systems such as the lungs and gastrointestinal (GI) tract have their unique biological barriers that hinder the passage of certain NP drug delivery systems, making it difficult to achieve specific accumulation. For instance, although oral delivery is the most widely used and highly accepted form of drug delivery, but acidic conditions and a large number of degradative enzymes in the GI tract system can restrict the passage of some drugs, rendering them inactive before being absorbed, which results in drugs with low stability and low bioavailability are not easily absorbed in the GI tract and have difficulty reaching therapeutic levels in the blood.…”

Section: The Limitations/challenges Of Nanotechnology Applicationmentioning

confidence: 99%

See 1 more Smart Citation

Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment

Huang,

Guo,

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Inflammation-associated diseases encompass a range of infectious diseases and non-infectious inflammatory diseases, which continuously pose one of the most serious threats to human health, attributed to factors such as the emergence of new pathogens, increasing drug resistance, changes in living environments and lifestyles, and the aging population. Despite rapid advancements in mechanistic research and drug development for these diseases, current treatments often have limited efficacy and notable side effects, necessitating the development of more effective and targeted anti-inflammatory therapies. In recent years, the rapid development of nanotechnology has provided crucial technological support for the prevention, treatment, and detection of inflammation-associated diseases. Various types of nanoparticles (NPs) play significant roles, serving as vaccine vehicles to enhance immunogenicity and as drug carriers to improve targeting and bioavailability. NPs can also directly combat pathogens and inflammation. In addition, nanotechnology has facilitated the development of biosensors for pathogen detection and imaging techniques for inflammatory diseases. This review categorizes and characterizes different types of NPs, summarizes their applications in the prevention, treatment, and detection of infectious and inflammatory diseases. It also discusses the challenges associated with clinical translation in this field and explores the latest developments and prospects. In conclusion, nanotechnology opens up new possibilities for the comprehensive management of infectious and inflammatory diseases.

show abstract

Section: Advanced Nanotechnologiesmentioning

confidence: 99%

Section: The Limitations/challenges Of Nanotechnology Applicationmentioning

confidence: 99%

Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment

Huang,

Guo,

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…Common delivery systems include protamine, lipoplex (LPX), 64 lipopolyplex (LPP), 65 virus-like particles (VLPs), 66 dendritic cell, 67 and LNPs. 68 Due to its most advanced status in current application, this review primarily focuses on the application of LNP technology.…”

Section: Delivery Platformsmentioning

confidence: 99%

Recent progress in mRNA cancer vaccines

Yao,

Xie,

Xia

2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The research and development of messenger RNA (mRNA) cancer vaccines have gradually overcome numerous challenges through the application of personalized cancer antigens, structural optimization of mRNA, and the development of alternative RNA-based vectors and efficient targeted delivery vectors. Clinical trials are currently underway for various cancer vaccines that encode tumor-associated antigens (TAAs), tumor-specific antigens (TSAs), or immunomodulators. In this paper, we summarize the optimization of mRNA and the emergence of RNA-based expression vectors in cancer vaccines. We begin by reviewing the advancement and utilization of state-of-the-art targeted lipid nanoparticles (LNPs), followed by presenting the primary classifications and clinical applications of mRNA cancer vaccines. Collectively, mRNA vaccines are emerging as a central focus in cancer immunotherapy, offering the potential to address multiple challenges in cancer treatment, either as standalone therapies or in combination with current cancer treatments.

show abstract

“…The sequences of COVID-19 mRNA vaccines are optimized to reduce the production of proinflammatory type I interferons [ 9 ]. For example, the uridine is replaced with purified N1-methyl-pseudouridine (1MΨ); mRNA vaccine BNT162Tech contains human α-globin RNA with optimized Kozak sequence in 5′ UTR domain, whereas mRNA vaccine CVnCoV contains artifacts from restriction and transcription site plus Kozak sequence [ 65 ].…”

Section: Modification Purification and Delivery Of Ivt Mrnamentioning

confidence: 99%

Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy

Zhao,

Gan,

et al. 2023

J Transl Med

View full text Add to dashboard Cite

Antibody technology is widely used in the fields of biomedical and clinical therapies. Nonetheless, the complex in vitro expression of recombinant proteins, long production cycles, and harsh storage conditions have limited their applications in medicine, especially in clinical therapies. Recently, this dilemma has been overcome to a certain extent by the development of mRNA delivery systems, in which antibody-encoding mRNAs are enclosed in nanomaterials and delivered to the body. On entering the cytoplasm, the mRNAs immediately bind to ribosomes and undergo translation and post-translational modifications. This process produces monoclonal or bispecific antibodies that act directly on the patient. Additionally, it eliminates the cumbersome process of in vitro protein expression and extends the half-life of short-lived proteins, which significantly reduces the cost and duration of antibody production. This review focuses on the benefits and drawbacks of mRNA antibodies compared with the traditional in vitro expressed antibodies. In addition, it elucidates the progress of mRNA antibodies in the prevention of infectious diseases and oncology therapy.

show abstract

Development and applications of mRNA treatment based on lipid nanoparticles

Cited by 22 publications

References 204 publications

Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment

Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment

Recent progress in mRNA cancer vaccines

Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy

Contact Info

Product

Resources

About